SCYX
NASDAQ HealthcareSCYNEXIS, Inc. - Common Stock
Drug Manufacturers - Specialty & Generic
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
๐ Market Data
| Price | $5.09 |
|---|---|
| Volume | 127,021 |
| Market Cap | 50.64M |
| Beta | 1.100 |
| RSI (14-Day) | 74.4 Overbought |
| 200-Day MA | $5.68 |
| 50-Day MA | $4.39 |
| 52-Week High | $10.48 |
| 52-Week Low | $3.53 |
| Forward P/E | -2.20 |
| Price / Book | 0.96 |
๐ฏ Investment Strategy Scores
SCYX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (89/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Institutional Whale (1/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find SCYX in your text
Paste any article, transcript, or post โ the tool will extract SCYX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.